Public Interest Provisions in Intellectual Property Laws

Intellectual property rights exist to reward creators – to give inventors, authors, and innovators a fair return on their effort. But what happens when those exclusive rights stand in the way of public access to life-saving medicines, affordable education, or critical research? Indian IP law has a clear answer: it builds in specific provisions that limit or override private IP rights when the public interest demands it. These aren’t loopholes or afterthoughts – they are deliberate, carefully structured mechanisms that sit at the heart of how India balances rewarding creators with protecting society at large.

Why public interest provisions exist in IP law 🔗

IP rights are essentially state-granted monopolies. A patent gives an inventor the exclusive right to exploit an invention for up to 20 years. Copyright gives an author control over their work for decades. These monopolies encourage innovation – but they can also lead to abuse, such as pricing medicines out of reach or restricting access to knowledge. Compulsory licensing and similar provisions exist precisely to address these situations – cases where an innovation that could greatly benefit the public is not being made available, or not at a price ordinary people can afford. Indian law, drawing from both domestic priorities and international frameworks like the TRIPS Agreement, embeds several such public interest safeguards across its major IP statutes.

Compulsory licensing under the Patents Act, 1970 🔗

The most prominent public interest tool in Indian patent law is compulsory licensing. Under the Patents Act, 1970, the government can authorize a third party to manufacture or sell a patented invention without the patent holder’s consent. This is not something that happens arbitrarily – the law sets out specific grounds and a structured procedure.

Section 84: the main compulsory licensing provision 🔗

Section 84(1) of the Patents Act allows any interested person to apply for a compulsory license after three years from the date a patent is granted. The Controller of Patents can grant such a license if any one of three conditions is met: the reasonable requirements of the public have not been satisfied; the patented invention is not available at a reasonably affordable price; or the patented invention has not been worked within India. These grounds reflect the law’s core expectation – that a patent is not a licence to sit on an invention. A patent holder who neither manufactures in India nor makes the product accessible at fair prices risks having that control taken away in the public interest.

India’s first compulsory license: the Natco-Bayer case 🔗

The most significant real-world application of this provision came in 2012. India’s Patent Office granted the first-ever compulsory license to Natco Pharma for the generic production of Sorafenib Tosylate – a cancer drug patented by Bayer used to treat liver and kidney cancer. Bayer’s branded version cost approximately ₹2.8 lakh per month of treatment, which was completely unaffordable for most patients. Natco offered to sell the same drug for around ₹9,000 per month. The Controller found that all three conditions under Section 84 were satisfied: the public’s needs were unmet, the price was unreasonable, and the drug was not being manufactured in India. This landmark decision reinforced that patents must serve public interest, not just commercial motives.

Sections 92 and 92A: emergencies and global access 🔗

Beyond ordinary compulsory licenses, the Patents Act has provisions tailored for emergency situations. Section 92A, introduced in 2005, allows the grant of compulsory licenses specifically to manufacture and export patented pharmaceutical products to countries that lack sufficient manufacturing capacity to address public health problems. This is what earns India its reputation as the “pharmacy of the world.” The provision directly implements the Doha Declaration on TRIPS and Public Health, allowing Indian generic manufacturers to legally supply affordable medicines to least-developed countries dealing with diseases like HIV/AIDS, tuberculosis, and malaria. Section 92 separately empowers the Central Government to notify circumstances – including national emergencies – under which the normal three-year waiting period is bypassed entirely, and licenses can be granted immediately to keep prices as low as possible.

Government use of patented inventions 🔗

Compulsory licensing involves a third party manufacturing a product. But what if the government itself needs to use a patented invention? That is where Section 100 of the Patents Act becomes relevant. It empowers the Central Government to use or authorize the use of any patented invention for government purposes, even without the patent holder’s prior consent. If the invention was independently developed by a government undertaking before the patent’s priority date, such use can even be royalty-free. In other cases, the patentee is entitled to adequate remuneration, to be agreed upon between the parties or, if not, determined by the High Court. This provision ensures that the state can access technology it needs for defence, public health, or national infrastructure without being held hostage to patent rights – while still providing patentees a fair compensation mechanism.

Exceptions for research and education: Section 52 of the Copyright Act, 1957 🔗

Public interest provisions are not limited to patent law. The Copyright Act, 1957 contains a crucial set of exceptions under Section 52 that carve out space for education, research, and the free flow of information – areas where rigidly enforcing copyright would cause serious harm to society.

Fair dealing for research and personal use 🔗

Section 52(1)(a) of the Copyright Act explicitly provides that fair dealing with any work – other than a computer programme – for purposes of private or personal use including research, or for criticism and review, does not amount to copyright infringement. The term “fair dealing” is deliberately not defined in the Act; courts assess it on a case-by-case basis by looking at factors like how much of the work was used, for what purpose, and whether it substituted the original in any commercial sense. The idea is straightforward: a researcher quoting from a published paper, or a student reproducing a short passage for study purposes, should not face copyright liability. The law protects these everyday acts of learning.

Educational exceptions and the Delhi University photocopy case 🔗

Section 52 goes further in protecting educational use. It permits reproduction of copyrighted material by teachers and pupils during instruction, and for performances at educational institutions. A landmark case that tested these boundaries was the Oxford University Press v. Rameshwari Photocopy Services dispute, where international publishers sued a Delhi University photocopy shop for reproducing extracts from their books as course packs for students. The Delhi High Court dismissed the suit, holding that the action fell within the educational exceptions under Section 52(1)(i). The court held that the fairness of such use in an educational context should be assessed on the standard of “extent justified by the purpose of education” – meaning that however much material is genuinely needed to teach students effectively, its use can be considered fair. This ruling had far-reaching implications for how universities and libraries across India operate.

The 2012 amendment: broadening the scope 🔗

The Copyright (Amendment) Act, 2012 significantly expanded the reach of Section 52. It extended fair dealing to cover all types of works, including sound recordings and films – previously, many of these were in a grey zone. It also introduced a specific exception for persons with disabilities under Section 52(1)(zb), and a compulsory licensing provision under Section 31B to enable the creation of accessible-format copies for the visually impaired and others. These changes brought India’s copyright law in line with international agreements, including the Berne Convention, and reflected a conscious policy choice to ensure that copyright protection does not impede access for those who are already disadvantaged.

The TRIPS framework: India’s international obligations and flexibility 🔗

India’s public interest provisions do not exist in isolation. They are shaped – and, equally importantly, enabled – by the international TRIPS Agreement administered by the WTO. TRIPS allows member states to issue compulsory licenses provided certain procedural conditions are met: the applicant must first attempt to negotiate a voluntary license with the patent holder, the use must be predominantly to supply the domestic market, and adequate remuneration must be paid to the patent holder. The Doha Declaration of 2001 further clarified that TRIPS should be interpreted to support members’ rights to protect public health, and that each country has the flexibility to define grounds for compulsory licensing according to its domestic needs. India has used this flexibility fully – embedding strong public interest protections while remaining TRIPS-compliant.

Balancing the equation: what these provisions actually achieve 🔗

A common concern is that public interest provisions might undermine the incentive to innovate. If a company’s patent can be overridden, why invest in research? The law’s answer lies in the carefully designed limits on these provisions. Compulsory licenses under Section 84 can only be sought three years after a patent is granted. The government pays remuneration even when using patents under Section 100. Fair dealing under copyright applies only to specific, non-commercial purposes. These are not blanket overrides of IP rights – they are targeted interventions for situations where the rights holder has either failed to meet public needs or where the public interest unambiguously outweighs the private right. The primary objective is always to promote public interest while keeping the overall IP system functional and fair for creators. The law is structured so that these provisions are used sparingly, and in practice, they have been – India has granted only one formal compulsory license in its entire history under the Patents Act.

What makes India’s approach notable is that it takes seriously both sides of the IP bargain. Creators and inventors deserve protection and reward – but that protection cannot come at the cost of public health, education, or access to knowledge. The provisions discussed here are the law’s way of holding both commitments at once.

What do you think? If a life-saving drug is patented but priced beyond the reach of most Indians, should compulsory licensing be invoked more readily – or does doing so risk discouraging pharmaceutical companies from investing in research for diseases that primarily affect lower-income populations? And in the context of education, where exactly should the line be drawn between fair dealing and infringement when digital course materials are shared freely across thousands of students?

References

1. https://intellectual-property-helpdesk.ec.europa.eu/news-events/news/compulsory-licensing-india-and-changes-brought-it-trips-agreement-2021-10-12_en
2. https://en.wikipedia.org/wiki/Compulsory_license
3. https://legalblogs.wolterskluwer.com/patent-blog/compulsory-license-india/
4. https://www.iiprd.com/grant-of-compulsory-license-in-india-its-provisions-and-need-in-several-industries-in-india/
5. https://www.rkdewan.com/blogs/compulsory-licensing-under-indian-patent-act/
6. https://brainiac.co.in/compulsory-licensing-and-public-interest-in-india/
7. https://indiankanoon.org/doc/252755/
8. https://copyright.gov.in/Exceptions.aspx
9. https://hollaassociates.in/fair-use-and-fair-dealing-in-copyright-law/
10. https://thelegalschool.in/blog/section-52-of-copyright-act
11. https://www.parkerip.com/blog/compulsory-licensing-under-the-patents-act-in-india/